| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maria Grazia Cascio, Daniele Bolognini, Roger G Pertwee, Enza Palazzo, Federico Corelli, Serena Pasquini, Vincenzo Di Marzo, Sabatino Maion. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. Pharmacological research. vol 61. issue 4. 2010-06-17. PMID:19961936. |
we have previously developed quinolone-3-carboxamides with the aim of obtaining new ligands for both cannabinoid receptors, cb1 and cb2. |
2010-06-17 |
2023-08-12 |
mouse |
| Maria Grazia Cascio, Daniele Bolognini, Roger G Pertwee, Enza Palazzo, Federico Corelli, Serena Pasquini, Vincenzo Di Marzo, Sabatino Maion. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. Pharmacological research. vol 61. issue 4. 2010-06-17. PMID:19961936. |
these results identify in 2 and 3 two novel, potent and selective cb2 antagonists/inverse agonists and confirm previous reports in the literature that, in addition to agonists at cannabinoid cb2 receptors, also inverse agonists/antagonists at these receptors show promise as anti-inflammatory agents. |
2010-06-17 |
2023-08-12 |
mouse |
| John C Ashton, Michelle Glas. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Current neuropharmacology. vol 5. issue 2. 2010-06-10. PMID:18615177. |
the cannabinoid cb2 receptor as a target for inflammation-dependent neurodegeneration. |
2010-06-10 |
2023-08-12 |
human |
| John C Ashton, Michelle Glas. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Current neuropharmacology. vol 5. issue 2. 2010-06-10. PMID:18615177. |
we have found that cannabinoid cb2 receptors are up-regulated during the activation of microglia following brain injury. |
2010-06-10 |
2023-08-12 |
human |
| Zahida Qamri, Anju Preet, Mohd W Nasser, Caroline E Bass, Gustavo Leone, Sanford H Barsky, Ramesh K Ganj. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Molecular cancer therapeutics. vol 8. issue 11. 2010-05-27. PMID:19887554. |
we have shown that the cannabinoid receptors cb1 and cb2 are overexpressed in primary human breast tumors compared with normal breast tissue. |
2010-05-27 |
2023-08-12 |
mouse |
| Masayuki Fujinaga, Katsushi Kumata, Kazuhiko Yanamoto, Kazunori Kawamura, Tomoteru Yamasaki, Joji Yui, Akiko Hatori, Masanao Ogawa, Yuichiro Yoshida, Nobuki Nengaki, Jun Maeda, Ming-Rong Zhan. Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor. Bioorganic & medicinal chemistry letters. vol 20. issue 5. 2010-05-27. PMID:20137936. |
two novel triaryl ligands 2 and 5 with potent in vitro binding affinities for the cannabinoid subtype-2 (cb2) receptor were labeled with a positron-emitting radioactive nuclide (11)c. radioligands [(11)c]2, [(11)c]5, and their analogs [(11)c]3 and [(11)c]4 were synthesized by o-[(11)c]methylation of their corresponding phenol precursors with [(11)c]ch(3)i. |
2010-05-27 |
2023-08-12 |
mouse |
| Joshua E Heller, Darric E Baty, Ming Zhang, Hongbo Li, Martin Adler, Doina Ganea, John Gaughan, Christopher M Loftus, Jack I Jallo, Ronald F Tum. The combination of selective inhibition of the cannabinoid CB1 receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury. Clinical neurosurgery. vol 56. 2010-05-18. PMID:20214038. |
the combination of selective inhibition of the cannabinoid cb1 receptor and activation of the cannabinoid cb2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury. |
2010-05-18 |
2023-08-12 |
mouse |
| Luciano De Petrocellis, Vincenzo Di Marz. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 5. issue 1. 2010-05-11. PMID:19847654. |
the molecular mechanism of action of delta(9)-tetrahydrocannabinol (thc), the psychotropic constituent of cannabis, has been a puzzle during the three decades separating its characterization, in 1964, and the cloning, in the 1990s, of cannabinoid cb1 and cb2 receptors. |
2010-05-11 |
2023-08-12 |
Not clear |
| Luciano De Petrocellis, Vincenzo Di Marz. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 5. issue 1. 2010-05-11. PMID:19847654. |
however, while these latter proteins do mediate most of the pharmacological actions of thc, they do not seem to act as receptors for other plant cannabinoids (phytocannabinoids), nor are they the unique targets of the endogenous lipids that were originally identified in animals as agonists of cb1 and cb2 receptors, and named endocannabinoids. |
2010-05-11 |
2023-08-12 |
Not clear |
| Elisa Torres, Maria Dolores Gutierrez-Lopez, Erika Borcel, Ines Peraile, Andrea Mayado, Esther O'Shea, Maria Isabel Colad. Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. Journal of neurochemistry. vol 113. issue 1. 2010-04-30. PMID:20067581. |
evidence that mdma ('ecstasy') increases cannabinoid cb2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. |
2010-04-30 |
2023-08-12 |
rat |
| Elisa Torres, Maria Dolores Gutierrez-Lopez, Erika Borcel, Ines Peraile, Andrea Mayado, Esther O'Shea, Maria Isabel Colad. Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. Journal of neurochemistry. vol 113. issue 1. 2010-04-30. PMID:20067581. |
over-expression of the cannabinoid cb2 receptor in microglia during non-immune and immune pathological conditions is thought to be aimed at controlling the production of neurotoxic factors such as proinflammatory cytokines. |
2010-04-30 |
2023-08-12 |
rat |
| Orazio Mazzoni, Maria V Diurno, Antonio M di Bosco, Ettore Novellino, Paolo Grieco, Giovanni Esposito, Alessia Bertamino, Antonio Calignano, Roberto Russ. Synthesis and pharmacological evaluation of analogs of indole-based cannabimimetic agents. Chemical biology & drug design. vol 75. issue 1. 2010-04-27. PMID:19895505. |
with the aim of investigating the structure-activity relationships (sar) for the binding of non-classical agonists to cb1 and cb2 cannabinoid receptors, we designed and synthesized a series of indole derivatives. |
2010-04-27 |
2023-08-12 |
Not clear |
| Shuxian Jiang, Yigong Fu, John Williams, Jodianne Wood, Lakshmipathi Pandarinathan, Shiri Avraham, Alexandros Makriyannis, Shalom Avraham, Hava Karsenty Avraha. Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PloS one. vol 2. issue 7. 2010-04-23. PMID:17653268. |
expression and function of cannabinoid receptors cb1 and cb2 and their cognate cannabinoid ligands in murine embryonic stem cells. |
2010-04-23 |
2023-08-12 |
Not clear |
| David A Price, Alex A Martinez, Alexandre Seillier, Wouter Koek, Yolanda Acosta, Elizabeth Fernandez, Randy Strong, Beat Lutz, Giovanni Marsicano, James L Roberts, Andrea Giuffrid. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. The European journal of neuroscience. vol 29. issue 11. 2010-04-19. PMID:19490092. |
at 3 days post-mptp, we found significant microglial activation and up-regulation of cb2 cannabinoid receptors in the ventral midbrain. |
2010-04-19 |
2023-08-12 |
mouse |
| David A Price, Alex A Martinez, Alexandre Seillier, Wouter Koek, Yolanda Acosta, Elizabeth Fernandez, Randy Strong, Beat Lutz, Giovanni Marsicano, James L Roberts, Andrea Giuffrid. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. The European journal of neuroscience. vol 29. issue 11. 2010-04-19. PMID:19490092. |
in conclusion, our data indicate that agonism at cb2 cannabinoid receptors protects against mptp-induced nigrostriatal degeneration by inhibiting microglial activation/infiltration and suggest that cb2 receptors represent a new therapeutic target to slow the degenerative process occurring in pd. |
2010-04-19 |
2023-08-12 |
mouse |
| Maurizio Guida, Alessia Ligresti, Daniele De Filippis, Alessandra D'Amico, Stefania Petrosino, Mariateresa Cipriano, Giuseppe Bifulco, Sara Simonetti, Pierangelo Orlando, Luigi Insabato, Carmine Nappi, Attilio Di Spiezio Sardo, Vincenzo Di Marzo, Teresa Iuvon. The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology. vol 151. issue 3. 2010-03-26. PMID:20133454. |
the levels of the endocannabinoid receptor cb2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. |
2010-03-26 |
2023-08-12 |
human |
| Stefania Petrosino, Vincenzo Di Marz. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Current opinion in investigational drugs (London, England : 2000). vol 11. issue 1. 2010-03-23. PMID:20047159. |
following the identification of receptors for thc - the cannabinoid cb1 and cb2 receptors - in mammals, various pharmaceutical strategies have attempted to exploit the properties of the cannabinoid system while minimizing psychotropic side effects. |
2010-03-23 |
2023-08-12 |
Not clear |
| Stefania Petrosino, Vincenzo Di Marz. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Current opinion in investigational drugs (London, England : 2000). vol 11. issue 1. 2010-03-23. PMID:20047159. |
the cloning of the cannabinoid cb1 and cb2 receptors enabled the discovery of the endogenous agonists of the receptors, the endocannabinoids, and eventually led to the identification of enzymes that catalyze endocannabinoid inactivation. |
2010-03-23 |
2023-08-12 |
Not clear |
| Diego Centonze, Francesco Mori, Giacomo Koch, Fabio Buttari, Claudia Codecà, Silvia Rossi, Maria Teresa Cencioni, Monica Bari, Stefania Fiore, Giorgio Bernardi, Luca Battistini, Mauro Maccarron. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 30. issue 6. 2010-03-22. PMID:19768368. |
this compound also failed to affect the synthesis and the degradation of the endocannabinoid anandamide, as well as the expression of both cb1 and cb2 cannabinoid receptors in various subpopulations of peripheral lymphocytes. |
2010-03-22 |
2023-08-12 |
Not clear |
| Itai Bab, Andreas Zimmer, Eitan Melame. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Annals of medicine. vol 41. issue 8. 2010-03-09. PMID:19634029. |
the active component of marijuana, delta(9)-tetrahydrocannabinol, activates the cb1 and cb2 cannabinoid receptors, thus mimicking the action of endogenous cannabinoids. |
2010-03-09 |
2023-08-12 |
mouse |